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General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware 
unless otherwise noted. Tris(dibenzylidene)acetone dipalladium, tri(2-furyl)phosphine, and (S)-
Siphos-PE were purchased from Strem Chemical Co. and used without purification. 
Tricyclohexylphosphonium tetrafluoroborate was purchased from Acros Chemical Co. and used 
without further purification. 2-Di-tert-butylphosphino-3,4,5,6-tetramethyl-2’,4’,6’-triisopropyl-1,1’-
biphenyl was purchased from Sigma-Aldrich and used without further purification. All other 
reagents were obtained from commercial sources and were used as obtained unless otherwise 
noted. NaOtBu and CuCl were stored in the glove box and removed prior to use. BF3OEt2 and 
POCl3 were purified by distillation under N2 prior to use. (Z)-1-bromobutene[1] was prepared 
according to a slight modification of a literature procedure; the preparation was conducted at rt 
instead of using microwave heating. (Z)-1-bromohexene,[2] and (E)-1-bromohexene[2] were 
prepared according to published procedures. Toluene, THF, diethyl ether and dichloromethane 
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were purified using a GlassContour solvent purification system. Yields refer to isolated yields of 
compounds estimated to be ≥95% pure as determined by 
1
H NMR analysis unless otherwise 
noted. The yields reported in the supporting information describe the result of a single 
experiment, whereas yields reported in Tables 1–2, Scheme 2, and Equation 1 are average 
yields of two or more experiments. Thus, the yields reported in the supporting information may 
differ from those shown in Tables 1–2, Scheme 2, and Equation 1. Structural and 
stereochemical assignments were made on the basis of 2-D COSY, and NOESY experiments. 
Ratios of diastereomers were determined by 1H NMR analysis. The reported optical rotation 
values refer to measurements taken of the isolated mixtures of diastereomers upon which 
chemical yields were based. Ratios of enantiomers were determined by HPLC analysis. 
Although diastereomers were not easily separable by chromatography, for most examples (with 
the exception of 8i and 8j) it was possible to separate small amounts of the pure (>20:1 dr) 
major diastereomer for chiral HPLC analysis. 
 
Preparation and Characterization of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide 
Substrates 
 
HN Boc
 
(±)-tert-Butyl octa-1,7-dien-4-ylcarbamate (S1). The title compound was prepared by 
modifying a procedure published by Veenstra.[3] A flame-dried flask was cooled under a stream 
of N2, charged with dichloromethane (60 mL) and cooled to 0 OC. Pent-4-enal (2.96 mL, 30 
mmol), allyltrimethylsilane (4.77 mL, 30 mmol) and tert-butyl carbamate (3.5 g, 30 mmol) were 
added to the flask and the resulting solution was stirred for 15 min at 0 OC. Distilled BF3OEt2 
(2.3 mL, 18 mmol) was added and the reaction mixture was stirred for 30 min at 0 OC. The 
mixture was gradually warmed to rt and stirred for 30 min. The reaction was then quenched with 
saturated aqueous NaHCO3 (20 mL) and stirred for 5 min at rt. The mixture was transferred to a 
separatory funnel and the layers were separated. The organic layer was washed with saturated 
aqueous NaHCO3 (20 mL) and then the combined aqueous layers were extracted with 
dichloromethane (15 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 3.8 g (56%) of the title compound as a clear colorless oil. 
This compound was found to exist as a mixture of rotamers as judged by 1H and 13C NMR 
analysis; data are for the mixture.  1H NMR (500 MHz, CDCl3) δ 5.84–5.73 (m, 2 H), 5.10–4.95 
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(m, 4 H), 4.33 (d, br, J = 7.5 Hz, 1 H), 3.66 (d, br, J = 4.5 Hz, 1 H), 2.26–2.07 (m, 4 H), 1.60–
1.55 (m, 1 H), 1.48–1.40 (m, 1 H), 1.43 (s, 9 H); 13C NMR (175 MHz, CDCl3) δ 155.5, 138.0, 
134.4, 117.7, 114.9, 79.0, 49.6, 39.5, 33.9, 30.2, 28.4; IR (film) 3337,1684 cm–1. MS (ESI) 
248.1621 (248.1621 calcd for C13H23NO2, M + Na+). 
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(±)-(E,2R*,5S*)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2). A 
flame-dried Schlenk flask was cooled under a stream of N2 and charged with Pd2(dba)3 (81 mg, 
0.089 mmol), tri(2-furyl)phosphine (82 mg, 0.36 mmol) and NaOtBu (853 mg, 8.9 mmol). The 
flask was purged with N2, then a solution of S1 (1.0 g, 4.4 mmol) in freshly distilled xylenes (22.2 
mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. (E)-(2-
bromovinyl)trimethylsilane (1.36 mL, 8.9 mmol) was added and the flask was heated to 137 ºC 
and stirred overnight (ca. 14 h). The mixture was cooled to room temperature and saturated 
aqueous NH4Cl (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the 
organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl 
acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to 
afford 1.11 g (77%) of the title compound as a dark red-brown oil. This compound was found to 
exist as a mixture of rotamers as judged by 1H and 13C NMR analysis; data are for the mixture. 
1H NMR (500 MHz, CDCl3) δ 5.98–5.92 (m, 1 H), 5.78–5.70 (m, 1 H), 5.68 (d, J = 18.5 Hz, 1 H), 
5.06–5.01 (m, 2 H), 3.92–3.68 (m, 2 H), 2.64–2.41 (m, 2 H), 2.34 (dt, J = 8.0, 13.0 Hz, 1 H), 
2.09 (dt, J = 8.0, 13.0 Hz, 1 H), 1.87–1.82 (m, 2 H), 1.68–1.64 (m, 2 H), 1.46 (s, 9 H), 0.03 (s, 9 
H); 13C NMR (125 MHz, CDCl3) δ 154.7, 143.2, 135.4, 132.9, 116.8, 79.0, 58.0, 57.9, 42.1, 42.0, 
40.0, 39.8, 28.5, –1.2; IR (film) 1692 cm–1. MS (ESI) 346.2174 (346.2173 calcd for C18H33NO2Si, 
M + Na+). 
 
General Procedure for Synthesis of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide 
Substrates 7. A round-bottom flask equipped with a stirbar was charged with S2  (1.0 equiv) 
and dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was added to the flask and the 
mixture was heated to reflux and stirred overnight. The solution was cooled to rt, diluted with 
water, basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
 S4 
product was dissolved in dichloromethane (0.2 M) and the appropriate isocyanate (1.1 equiv) 
was added. The reaction mixture was stirred at rt until starting material had been completely 
consumed as judged by TLC analysis (ca. 1 h). The crude reaction mixture was concentrated in 
vacuo, and purified by flash chromatography on silica gel. 
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(2S,5R)-2,5-Diallyl-N-(4-methoxyphenyl)pyrrolidine-1-carboxamide (7a). The title compound 
was prepared from S2 (2.13 g, 6.6 mmol) and 4-methoxyphenyl isocyanate (940 µL, 7.3 mmol) 
in two steps via the general procedure described above. This procedure afforded 1.2 g (61%) of 
the title compound as a white solid: mp = 63–65 ºC. 1H NMR (700 MHz, CDCl3) δ 7.25 (d, J = 
8.4 Hz, 2 H), 6.82 (d, J = 9.1 Hz, 2 H), 6.33 (s, 1H), 5.91–5.85 (m, 2 H), 5.20–5.15 (m, 4 H), 
3.99–3.96 (m, 2 H), 3.77 (s, 3 H), 2.55 (dt, J = 14.0, 7.0 Hz, 2 H), 2.24 (dt, J = 7.0, 14.0 Hz, 2 
H), 2.02–1.97 (m, 2 H), 1.78–1.74 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 155.5, 155.2, 135.2, 
132.3, 121.4, 118.0, 114.1, 58.8, 55.5, 40.2, 29.5; IR (film) 3311, 1635 cm–1. MS (ESI) 301.1917 
(301.1911 calcd for C18H24N2O2, M + H+).  
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(2S,5R)-2,5-Diallyl-N-(3,4-dimethoxyphenyl)pyrrolidine-1-carboxamide (7b). The title 
compound was prepared from S2 (965 mg, 2.98 mmol) and 3,4-dimethoxyphenyl isocyanate 
(488 µL, 3.3 mmol) in two steps via the general procedure described above. This procedure 
afforded 542 mg (55%) of the title compound as a tan solid: mp = 112–114 ºC.  1H NMR (500 
MHz, CDCl3) δ 7.27 (d, J = 2.1 Hz, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 6.62 (dd, J = 2.8, 8.4 Hz, 1 
H), 6.36 (s, 1H), 5.91–5.86 (m, 2 H), 5.21–5.16 (m, 4 H), 4.01–3.97 (m, 2 H), 3.88 (s, 3 H), 3.84 
(s, 3 H), 2.57 (dt, J = 6.3,13.3 Hz, 2 H), 2.25 (dt, J = 7.7, 13.3 Hz, 2 H), 2.03–1.99 (m, 2 H), 
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1.79–1.75 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 155.1, 149.1, 144.8, 135.2, 133.0, 118.1, 
111.4, 110.9, 104.7, 58.7, 56.2, 55.9, 40.2, 29.5; IR (film) 3327, 1635 cm–1. MS (ESI) 331.2018 
(331.2016 calcd for C19H26N2O3, M + H+). 
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(2S,5R)-2,5-Diallyl-N-(4-chlorophenyl)pyrrolidine-1-carboxamide (7c). The title compound 
was prepared from S2 (1.05 g, 3.2 mmol) and 4-chlorophenyl isocyanate (541 mg, 3.5 mmol) in 
two steps via the general procedure described above. This procedure afforded 574 mg (58%) of 
the title compound as a white solid: mp = 91–93 ºC. 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 
9.0 Hz, 2 H), 7.21 (d, J = 9.0 Hz, 2 H), 6.51 (s, 1H), 5.91–5.85 (m, 2 H), 5.22–5.16 (m, 4 H), 
4.00–3.95 (m, 2 H), 2.55 (dt, J = 14.0, 6.5 Hz, 2 H), 2.25 (dt, J = 14.0, 7.5 Hz, 2 H), 2.03–1.97 
(m, 2 H), 1.79–1.74 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 154.5, 137.9, 135.1, 128.7, 127.4, 
120.3, 118.3, 58.9, 40.1, 29.6; IR (film) 3318, 1640 cm–1. MS (ESI) 327.1242 (327.1235 calcd 
for C17H21ClN2O, M + Na+). 
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(2S,5R)-2,5-Diallyl-N-(4-bromophenyl)pyrrolidine-1-carboxamide (7d). The title compound 
was prepared from S2 (1.2 g, 3.7 mmol) and 4-bromophenyl isocyanate (806 mg, 4.1 mmol) in 
two steps via the general procedure described above. This procedure afforded 827 mg (64%) of 
the title compound as a off-white solid: mp = 101–104 ºC. 1H NMR (700 MHz, CDCl3) δ 7.37 (d, 
J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.91–5.85 (m, 2 H), 5.21–5.17 (m, 4 H), 
3.99–3.97 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 2.03–1.99 
(m, 2 H), 1.80–1.77 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 154.5, 138.4, 135.1, 131.7, 120.7, 
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118.3, 115.0, 58.9, 40.1, 29.6; IR (film) 3316, 1635 cm–1. MS (ESI) 349.0912 (349.0910 calcd 
for C17H21BrN2O, M + H+). 
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(2S,5R)-2,5-Diallyl-N-(4-cyanophenyl)pyrrolidine-1-carboxamide (7e). The title compound 
was prepared from S2 (1.12 g, 3.46 mmol) and 4-cyanophenyl isocyanate (549 mg, 3.81 mmol) 
in two steps via the general procedure described above. This procedure afforded 613 mg (60%) 
of the title compound as a off-white solid: mp = 76–79 ºC. 1H NMR (700 MHz, CDCl3) δ 7.36 (d, 
J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.92–5.86 (m, 2 H), 5.21–5.17 (m, 4 H), 
4.02–3.96 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 2.03–1.99 
(m, 2 H), 1.80–1.77 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.9, 143.5, 135.0, 133.1, 119.2, 
118.6, 118.6, 105.1, 59.1, 39.9, 29.6; IR (film) 3365, 1652 cm–1. MS (ESI) 296.1756 (296.1757 
calcd for C18H21N3O, M + H+). 
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(2S,5R)-2,5-Diallyl-N-(4-nitrophenyl)pyrrolidine-1-carboxamide (7f). The title compound was 
prepared from S2 (660 mg, 2.04 mmol) and 4-nitrophenyl isocyanate (368 mg, 2.24 mmol) in 
two steps via the general procedure described above. This procedure afforded 366 mg (57%) of 
the title compound as a pale-yellow solid: mp = 96–97 ºC. 1H NMR (700 MHz, CDCl3) δ 8.15 (d, 
J = 9.1 Hz, 2 H), 7.50 (d, J = 9.1 Hz, 2 H), 6.93 (s, 1H), 5.94–5.88 (m, 2 H), 5.25–5.21 (m, 4 H), 
4.04–4.01 (m, 2 H), 2.56 (dt, J = 7.0, 13.3 Hz, 2 H), 2.29 (dt, J = 7.0, 14.0 Hz, 2 H), 2.07–2.03 
(m, 2 H), 1.83–1.79 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.7, 145.5, 142.2, 135.0, 125.1, 
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118.8, 117.8, 59.2, 39.9, 29.7; IR (film) 3331, 1652 cm–1. MS (ESI) 316.1656 (316.1656 calcd 
for C17H21N3O3, M + H+). 
 
Preparation and Characterization of Bicyclic Urea Products 
 
General Procedure for Synthesis of Racemic Bicyclic Ureas (for HPLC assays). A flame-
dried Schlenk tube was cooled under vacuum and charged with the appropriate meso-N-aryl-
2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), Pd2(dba)3 (0.02 equiv), PCy3.HBF4 
(0.08 equiv), and NaOtBu (1.5 equiv). The flask was evacuated and purged with N2. Toluene 
(0.2 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The 
appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 ºC 
and stirred for 2 h. The mixture was cooled to room temperature and saturated aqueous NH4Cl 
(5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were added. The layers were 
separated, the organic layer was filtered through a plug of silica gel, and the silica gel was 
washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
 
General Procedure for Synthesis of Enantiomerically-Enriched Bicyclic Ureas 
A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate meso-
N-aryl-2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), Pd2(dba)3 (0.02 equiv), (S)-
Siphos-PE (0.08 equiv), and NaOtBu or NaOMe (1.5 equiv). The flask was evacuated and 
purged with N2. Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at 
rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was 
heated to 100 ºC. The solution was stirred for 2 h or until the starting material was completely 
consumed as judged by TLC analysis. The mixture was cooled to room temperature and 
saturated aqueous NH4Cl (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were 
added. 6 M HCl was used instead of NH4Cl to remove aniline side products if column 
chromatography could not separate the desired product from aniline side products. The layers 
were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was 
washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
 
 S8 
N
NO
H
H C2H5
OMe
H
 
(+)-(Z,3S,4aS,7R)-7-Allyl-2-(4-methoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8a). The general procedure was employed for the coupling of 7a (60 
mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 48 mg (68%) of the title compound as a brown oil and as a 7:1 mixture 
of diastereomers as determined by 1H NMR analysis: [α]23D +9.5 (c 4.3, CH2Cl2).  Data are for 
the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.14 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 
H), 5.77–5.71 (m, 1 H), 5.43 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.03 (d, J = 17.5 Hz, 
1 H), 5.00 (d, J = 9.8 Hz, 1 H), 3.99 (dt, J = 2.1, 9.1 Hz, 1 H), 3.82–3.78 (m, 1 H), 3.79 (s, 3 H), 
3.65 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.29–2.27 (m, 1 H), 2.18–
2.15 (m, 2 H), 2.08 (dt, J = 8.4, 13.3 Hz, 1 H) 1.99–1.88 (m, 4 H), 1.83 (dd, J = 6.3, 12.6 Hz, 1 
H) 1.68–1.60 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 157.6, 154.2, 
135.8, 135.1, 134.6, 129.3, 124.2, 116.8, 114.1, 58.3, 57.3, 55.4, 52.7, 37.8, 31.3, 31.0, 30.9, 
27.8, 20.7, 14.0; IR (film) 1642 cm–1. MS (ESI) 355.2382 (355.2380 calcd for C22H30N2O2, M + 
H+). The enantiopurity was determined to be 86:14 er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 2.5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 44.2 and 49.1 min). 
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(+)-(Z,3S,4aS,7R)-7-Allyl-2-(3,4-dimethoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8b). The general procedure was employed for the coupling of 7b (66 
mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 30 mg (39%) of the title compound as a brown oil and as a 7:1 mixture 
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of diastereomers as determined by 1H NMR analysis: [α]23D +7.0 (c 2.9, CH2Cl2).  Data are for 
the major isomer. 1H NMR (700 MHz, CDCl3) δ 6.83 (d, J = 8.4 Hz, 1 H), 6.78–6.77 (m, 2 H), 
5.77–5.71 (m, 1 H), 5.44 (dt, J = 7.0, 10.5 Hz, 1 H) 5.13–5.09 (m, 1 H), 5.03 (d, J = 16.8 Hz, 1 
H), 5.00 (d, J = 10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 9.1 Hz, 1 H), 3.86 (s, 6  H), 3.85–3.81 (m, 1 H), 
3.66 (ddt, J = 2.1, 5.6, 11.2 Hz, 1 H), 2.80 (dd, J = 5.6, 12.6 Hz, 1 H), 2.30–2.28 (m, 1 H), 2.18–
2.15 (m, 2 H), 2.07 (dt, J = 8.4, 13.3 Hz, 1 H) 2.00–1.96 (m, 1 H), 1.93–1.87 (m, 3 H), 1.83 (dd, 
J = 7.0, 12.6 Hz, 1 H) 1.69–1.63 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) 
δ 154.1, 148.9, 147.2, 135.8, 135.4, 134.7, 124.2, 120.1, 116.8, 112.3, 111.1, 58.5, 57.3, 56.0, 
55.9, 52.7, 37.8, 31.3, 31.1, 30.9, 27.7, 20.7, 14.1;  IR (film) 1641 cm–1. MS (ESI) 385.2486 
(385.2486 calcd for C23H32N2O3, M + H+). The enantiopurity was determined to be 82:18 er by 
chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 
nm, RT= 20.4 and 23.5 min). 
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(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8c). The general procedure was employed for the coupling of 7c (305 
mg, 1.0 mmol) and (Z)-1-bromobut-1-ene (750 µL, 1.5 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (18.3 mg, 0.02 mmol), and (S)-Siphos-PE (40.4 mg, 0.08 mmol). 
This procedure afforded 288 mg (80%) of the title compound as a yellow oil: [α]23D –14.3 (c 5.3, 
CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 7.31 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 5.77–
5.71 (m, 1 H), 5.45 (dt, J = 7.0, 10.5 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 16.8 Hz, 1 H), 
5.01 (d, J = 10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 9.1 Hz, 1 H), 3.90 (dt, J = 4.2, 10.5 Hz, 1 H), 3.66 
(ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, J 
= 9.1, 13.3 Hz, 1 H) 1.99 (dt, J = 6.3, 11.2 Hz, 1 H), 1.93–1.88 (m, 3 H), 1.84 (dd, J = 6.3, 12.6 
Hz, 1 H) 1.69–1.64 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.7, 
140.8, 135.6, 134.9, 131.2, 129.3, 128.9, 123.8, 117.0, 58.0, 57.4, 52.8, 37.7, 31.3, 31.0, 30.9, 
27.8, 20.7, 14.0;  IR (film) 1643 cm–1. MS (ESI) 359.1887 (359.1885 calcd for C21H27ClN2O, M + 
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H+). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 18.1 min). 
 
N
NO
H
H C2H5
Br
H
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-bromophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8d). The general procedure was employed for the coupling of 7d (70 
mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 15 mg (18%) of the title compound as a brown oil and as a 18:1 mixture 
of diastereomers as determined by 1H NMR analysis: [α]23D –21.1 (c 0.5, CH2Cl2). This material 
also contained ca. 20% of an unidentified side product. Data are for the major isomer.  1H NMR 
(700 MHz, CDCl3) δ 7.46 (d, J = 8.4 Hz, 2 H), 7.14 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 
(dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J = 10.5 Hz, 1 
H), 4.01 (dt, J = 2.8, 8.4 Hz, 1 H), 3.90 (dt, J = 4.9, 10.5 Hz, 1 H), 3.66 (ddt, J = 2.8, 5.6, 11.2 
Hz, 1 H), 2.78 (dd, J = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, J = 8.4, 13.3 Hz, 1 H) 
1.99 (dt, J = 5.6, 11.9 Hz, 1 H), 1.95–1.88 (m, 3 H), 1.84 (dd, J = 6.3, 12.6 Hz, 1 H) 1.69–1.63 
(m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.6, 141.4, 135.6, 134.9, 
131.9, 129.7, 123.8, 119.2, 117.0, 57.9, 57.4, 52.7, 37.7, 31.3, 31.0, 30.8, 27.7, 20.7, 14.0;  IR 
(film) 1645 cm–1. MS (ESI) 403.1379 (403.1380 calcd for C21H27BrN2O, M + H+). The 
enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 14.5 and 20.0 min). 
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H
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(–)-4-[(Z,3S,4aS,7R)-7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-
2(1H)-yl]benzonitrile (8e). The general procedure was employed for the coupling of 7e (59 mg, 
0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 29 mg (41%) of the title compound as a brown oil and as a 17:1 mixture 
of diastereomers as determined by 1H NMR analysis: [α]23D –71.0 (c 2.9, CH2Cl2). This material 
also contained ca. 5% of 4-aminobenzonitrile. Data are for the major isomer. 1H NMR (700 MHz, 
CDCl3) δ 7.62 (d, J = 9.1 Hz, 2 H), 7.39 (d, J = 9.1 Hz, 2 H), 5.76–5.71 (m, 1 H),  5.45 (dt, J = 
7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 16.1 Hz, 1 H), 5.02 (d, J = 9.1 Hz, 1 H), 4.07 
(dt, J = 4.9, 10.5 Hz, 1 H), 4.02 (dt, J = 2.1, 8.4, Hz 1 H), 3.68 (ddt, J = 2.1, 5.6, 11.2 Hz, 1 H), 
2.76 (dd, J = 6.3, 12.6 Hz, 1 H), 2.23 (d, J = 12.6 Hz, 1 H), 2.20–2.14 (m, 2 H), 2.06 (dt, J = 8.4, 
13.3 Hz, 1 H), 2.03–2.00 (m, 1 H), 1.97–1.85 (m, 4 H), 1.71–1.63 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 
H); 13C NMR (175 MHz, CDCl3) δ 153.1, 146.6, 135.3, 135.2, 132.6, 127.8, 123.4, 118.9, 117.2, 
108.5, 57.7, 57.4, 52.7, 37.4, 31.4, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1648 cm–1. MS (ESI) 
350.2227 (350.2227 calcd for C22H27N3O, M + H+). The enantiopurity was determined to be 94:6 
er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 
205 nm, RT= 33.2 and 42.9 min). 
 
N
NO
H
H C2H5
NO2
H
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-nitrophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8f). A modification of the general procedure was employed for the 
coupling of 7f (63 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in 
toluene), using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 
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mg, 0.016 mmol). In contrast to the general procedure, this reaction was run overnight (16 h) at 
120 oC. This procedure afforded 18 mg (24%) of the title compound as a yellow oil and as a 
20:1 mixture of diastereomers as determined by 1H NMR analysis: [α]23D –281.3 (c 1.1, CH2Cl2).  
This material also contained ca. 8% of unreacted starting material and ca. 3% of a bicyclic urea 
side product lacking the butenyl group (tentatively assigned as 7-allyl-3-methyl-2-(4-
nitrophenyl)-4a,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-1(2H)-one). Data are for the major 
isomer. 1H NMR (700 MHz, CDCl3) δ 8.21 (d, J = 9.1 Hz, 2 H), 7.46 (d, J = 9.1 Hz, 2 H), 5.77–
5.71 (m, 1 H), 5.46 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12 (ddt, J = 2.1, 8.4, 17.5 Hz, 1 H), 5.07–5.03 
(m, 2 H), 4.15 (dt, J = 4.,9 9.8 Hz, 1 H), 4.05 (dt, J = 2.8, 9.1 Hz, 1 H), 3.70 (ddt, J = 2.8, 5.6, 
11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 13.3 Hz, 1 H), 2.25 (d, J = 13.3 Hz, 1 H), 2.23–2.16 (m, 2 H), 
2.10–2.02 (m, 2 H) 1.97–1.87 (m, 4 H), 1.73–1.66 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 153.0, 148.5, 144.4, 135.3, 135.3, 127.2, 124.1, 123.3, 117.3, 57.8, 57.4, 
52.7, 37.3, 31.5, 31.0, 30.8, 27.7, 20.8, 14.0; IR (film) 1649 cm–1. MS (ESI) 370.2126 (370.2125 
calcd for C21H27N3O3, M + H+). The enantiopurity was determined to be 96:4 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 1.5 mL/min, λ 310 nm, RT= 19.1 
and 26.2 min). 
 
N
NO
H
H
Cl
H
C4H9
 
(–)-(E,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8g). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and (E)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in 
the workup to remove 4-chloroaniline side product. This procedure afforded 44 mg (57%) of the 
title compound as a yellow oil: [α]23D –30.3 (c 1.9, CH2Cl2). This material also contained ca. 15% 
of a regioisomeric bicyclic urea product generated from the coupling of 7c and 2-bromohex-1-
ene (tentatively assigned as (3S,4aS,7R)-7-allyl-2-(4-chlorophenyl)-3-(2-
methylenehexyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one). Data are for the major isomer.  1H 
NMR (500 MHz, CDCl3) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.17 (d, J = 9.0 Hz, 2 H), 5.78–5.70 (m, 1 
H), 5.41–5.36 (m, 1 H), 5.17–5.10 (m, 1 H), 5.05–5.00 (m, 2 H), 4.00 (dt, J = 2.5, 8.5 Hz, 1 H), 
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3.92–3.87 (m, 1 H), 3.65 (ddt, J = 2.5, 5.5, 11.0 Hz, 1 H), 2.79 (dd, J = 6.0, 13.5 Hz, 1 H), 2.28–
2.23 (m, 2 H), 2.10–1.98 (m, 3 H), 1.95–1.87 (m, 3 H), 1.84 (dd, J = 6.5, 12.5 Hz, 1 H) 1.69–
1.62 (m, 2 H), 1.29–1.26 (m, 4 H), 0.87 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 153.7, 
140.9, 135.6, 134.6, 131.2, 129.4, 128.8, 125.1, 116.9, 57.9, 57.4, 52.6, 37.7, 36.9, 32.2, 31.4, 
30.8, 27.8, 22.1, 13.9 (one carbon signal is absent due to incidental equivalence);  IR (film) 
1643 cm–1. MS (ESI) 387.2207 (387.2198 calcd for C23H31ClN2O, M + H+). The enantiopurity 
was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% 
IPA/Hexanes, 1.5 mL/min, λ 205 nm, RT= 20.0 and 37.5 min). 
 
N
NO
H
H C4H9
Cl
H
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8h). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and (Z)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in 
the workup to remove 4-chloroaniline side product. This procedure afforded 47 mg (61%) of the 
title compound as a yellow brown oil: [α]23D –14.8 (c 3.5, CH2Cl2). Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.31 (d, J = 9.1 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 
H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.15–5.11 (m, 1 H), 5.05–5.00 (m, 2 H), 4.01 (dt, J = 2.8, 8.4 
Hz, 1 H), 3.91–3.88 (m, 1 H), 3.66 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, J = 8.4, 13.3 Hz, 1 
H), 2.24–2.14 (m, 3 H), 2.07 (dt, J = 8.4, 14.0 Hz, 1 H), 2.00–1.97 (m, 1 H) 1.95–1.83 (m, 4 H), 
1.70–1.62 (m, 2 H), 1.25–1.24 (m, 4 H), 0.86 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 
153.7, 140.8, 135.6, 133.4, 131.3, 129.4, 128.9, 124.4, 117.0, 58.1, 57.4, 52.8, 37.7, 31.6, 31.3, 
31.0, 30.8, 27.8, 27.2, 22.3, 13.9;  IR (film) 1642 cm–1. MS (ESI) 387.2203 (387.2198 calcd for 
C23H31ClN2O, M + H+). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 254 nm, RT= 20.9 and 36.2 
min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8i). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 1-bromo-2-methyl-1-propene (31 µL, 0.3 mmol), using a catalyst composed 
of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure 
afforded 37 mg (52%) of the title compound as a yellow oil and as a 10:1 mixture of 
diastereomers as determined by 1H NMR analysis: [α]23D –37.9 (c 2.2, CH2Cl2). Data are for the 
major isomer.  1H NMR (700 MHz, CDCl3) δ 7.30 (d, J = 7.7 Hz, 2 H), 7.18 (d, J = 9.1 Hz, 2 H), 
5.74 (dddd, J = 6.3, 7.7, 10.5, 16.8 Hz, 1 H), 5.04 (dd, J = 2.1, 16.8 Hz, 1 H), 5.01 (d, J = 10.5 
Hz, 1 H), 4.89 (dt, J = 1.4, 7.0 Hz, 1 H), 4.00 (dt, J = 2.8, 9.1 Hz, 1 H), 3.88–3.85 (m, 1 H), 3.66 
(ddt, J = 2.8, 5.6, 11.2 Hz, 1 H), 2.79 (dd, J = 6.3, 12.6 Hz, 1 H), 2.21–2.16 (m, 2 H), 2.09–2.04 
(m, 2 H), 2.02–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.84 (dd, J = 7.0, 12.6 Hz, 1 H) 1.68–1.62 (m, 
2 H), 1.64 (s, 3 H), 1.47 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.7, 140.9, 135.6, 134.9, 
131.1, 129.3, 128.8, 119.6, 117.0, 58.3, 57.4, 52.8, 37.7, 32.2, 31.1, 30.9, 27.7, 25.7, 17.9; IR 
(film) 1643 cm–1. MS (ESI) 359.1895 (359.1885 calcd for C21H27ClN2O, M + H+). The 
enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 13.8 and 24.0 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylallyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8j). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 2-bromopropene (89 µL, 1.0 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 39 mg 
 S15 
(56%) of the title compound as a yellow oil and as a 20:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –33.5 (c 2.9, CH2Cl2). Data are for the major isomer.  1H 
NMR (700 MHz, CDCl3) δ 7.31 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 9.1 Hz, 2 H), 5.77–5.71 (m, 1 
H), 5.06–5.01 (m, 2 H), 4.79 (s, 1 H), 4.66 (s, 1 H), 4.09–4.06 (m, 1 H), 4.00 (dt, J = 2.8, 8.4 Hz, 
1 H), 3.66 (ddt, J = 2.8, 4.9, 11.2 Hz, 1 H), 2.79 (dd, J = 6.3, 12.6 Hz, 1 H), 2.27–2.23 (m, 2 H), 
2.12 (dd, J = 11.2, 14.0 Hz, 1 H) 2.07 (dt, J = 8.4, 13.3 Hz, 1 H), 2.03–1.99 (m, 1 H), 1.95–1.89 
(m, 1 H), 1.85 (dd, J = 7.0, 12.6 Hz, 1 H) 1.68–1.64 (m, 2 H), 1.55 (s, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 153.7, 141.5, 140.7, 135.6, 131.2, 129.3, 128.9, 117.0, 113.9, 57.5, 55.8, 52.6, 41.8, 
37.7, 30.8, 30.5, 27.8, 22.0; IR (film) 1641 cm–1. MS (ESI) 345.1735 (345.1728 calcd for 
C20H25ClN2O, M + H+). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 22.8 and 28.4 
min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methylbenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8k). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 4-bromotoluene (37 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg 
(83%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –125.6 (c 3.1, CH2Cl2).  Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.06 (d, J = 8.4 
Hz, 2 H), 6.86 (d, J = 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, J = 16.8 Hz, 1 H), 5.01 (d, J = 
10.5 Hz, 1 H), 4.10 (dt, J = 4.9 11.2 Hz, 1 H), 4.03 (dt, J = 2.8, 8.4, Hz 1 H), 3.76 (ddt, J = 2.8, 
5.6, 11.2 Hz, 1 H), 2.90 (dd, J = 2.8, 13.3 Hz, 1 H), 2.81–2.78 (m, 1 H), 2.53 (dd, J = 11.2, 14.0 
Hz, 1 H), 2.30 (s, 3 H), 2.09–2.04 (m, 2 H), 2.00 (dt, J = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 
1.85 (dd, J = 5.6, 12.6 Hz, 1 H) 1.64–1.59 (m, 1 H), 1.56 (dt, J = 6.3, 12.6 Hz, 1 H); 13C NMR 
(175 MHz, CDCl3) δ 153.6, 140.8, 136.2, 135.6, 134.5, 131.3, 129.3, 129.3, 129.0, 128.9, 117.0, 
59.8, 57.5, 52.6, 39.2, 37.6, 30.8, 30.1, 27.8, 21.0;  IR (film) 1642 cm–1. MS (ESI) 395.1887 
(395.1885 calcd for C24H27ClN2O, M + H+). The enantiopurity was determined to be 92:8 er by 
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chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 
nm, RT= 17.3 and 19.4 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methoxybenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8l). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 4-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 58 mg 
(70%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –169.4 (c 2.2, CH2Cl2).  Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.35 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 8.4 Hz, 2 H), 6.89 (d, J = 9.1 
Hz, 2 H), 6.79 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J = 
10.5 Hz, 1 H), 4.08 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.77–
3.72 (m, 1 H), 2.87 (dd, J = 3.5. 14.0 Hz, 1 H), 2.80 (dd, J = 6.3, 14.0 Hz, 1 H), 2.51 (dd, J = 
11.2, 13.3 Hz, 1 H), 2.09–2.04 (m, 2 H), 2.00 (dt, J = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 
1.85 (dd, J = 7.0, 12.6 Hz, 1 H) 1.65–1.54 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 158.3, 153.6, 
140.8, 135.6, 131.3, 130.0, 129.6, 129.3, 129.0, 117.0, 114.0, 59.9, 57.5, 55.2, 52.6, 38.7, 37.6, 
30.8, 30.1, 27.8; IR (film) 1642 cm–1. MS (ESI) 411.1834 (411.1834 calcd for C24H27ClN2O2, M + 
H+). The enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 204 nm, RT= 49.3 and 55.7 min). 
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(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)hexahydropyrrolo[1,2-c]pyrimidin-
1(2H)-one (8m). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) 
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and bromobenzene (32 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 
mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (83%) of the title 
compound as a pale brown foam oil and as a 7:1 mixture of diastereomers as determined by 1H 
NMR analysis: [α]23D –61.2 (c 5.6, CH2Cl2). Data are for the major isomer. 1H NMR (700 MHz, 
CDCl3) δ 7.36 (d, J = 9.1 Hz, 2 H), 7.27–7.25 (m, 4 H), 7.21–7.20 (m, 1 H), 6.98 (d, J = 7.0 Hz, 2 
H), 5.77–5.71 (m, 1 H), 5.05–5.00 (m, 2 H), 4.14 (dt, J = 4.9, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 
Hz, 1 H), 3.77 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.94 (dd, J = 3.5, 14.0 Hz, 1 H), 2.80 (dd, J = 6.3, 
13.3 Hz, 1 H), 2.57 (dd, J = 11.2, 14.0 Hz, 1 H), 2.10–2.04 (m, 2 H), 2.03–2.00 (m, 1 H), 1.97–
1.91 (m, 1 H), 1.86 (dd, J = 6.3, 12.6 Hz, 1 H) 1.66–1.54 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 
153.6, 140.8, 137.6, 135.6, 131.4, 129.3, 129.1, 129.0, 128.6, 126.6, 117.0, 59.7, 57.5, 52.7, 
39.6, 37.6, 30.8, 30.2, 27.8; IR (film) 1642 cm–1. MS (ESI) 381.1736 (381.1728 calcd for 
C23H25ClN2O, M + H+). The enantiopurity was determined to be 90:10 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 21.1 and 24.2 
min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8n). The general 
procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 4-bromobenzotriflouride 
(42 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-
PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (74%) of the title compound as a pale 
yellow oil and as a 5:1 mixture of diastereomers as determined by 1H NMR analysis: [α]23D –
46.1 (c 6.0, CH2Cl2).  Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.51 (d, J = 
7.7 Hz, 2 H), 7.36 (d, J = 9.1 Hz, 2 H), 7.24 (d, J = 9.1 Hz, 2 H), 7.09 (d, J = 7.7 Hz, 2 H), 5.77–
5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.16 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 9.1 Hz, 1 H), 
3.76 (ddt, J = 2.1, 5.6, 11.9 Hz, 1 H), 3.00 (dd, J = 3.5, 14.0 Hz, 1 H), 2.79 (dd, J = 5.6, 13.3 Hz, 
1 H), 2.66 (dd, J = 11.2, 13.3 Hz, 1 H), 2.09–2.00 (m, 3 H), 1.98–1.93 (m, 1 H), 1.87 (dd, J = 
6.3, 11.9 Hz, 1 H) 1.66–1.56 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.5, 141.7, 140.6, 135.5, 
131.6, 129.4, 129.3, 129.2 (q, J = 37 Hz), 129.1, 125.6 (q, 3.3 Hz), 124.0 (q, J = 270 Hz), 117.1, 
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59.5, 57.6, 52.6, 39.6, 37.6, 30.8, 30.3, 27.8;  IR (film) 1642 cm–1. MS (ESI) 449.1600 (449.1602 
calcd for C24H24ClF3N2O, M + H+). The enantiopurity was determined to be 85:15 er by chiral 
HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 
19.9 and 27.5 min). 
 
N
NO
H
H
Cl
H
CF3
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8n). A modified 
general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 4-
bromobenzotriflouride (42 µL, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 54 mg (60%) of the title compound as a pale yellow oil and as a 10:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D –51.1 (c 2.3, CH2Cl2).  The 
enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.4 and 26.7 min). Spectroscopic data 
were identical to those provided above. 
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H
H
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(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8o). The general 
procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 1-bromo-4-
(trifluoromethoxy)benzene (45 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 
0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (68%) of 
the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by 
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1H NMR analysis: [α]23D –48.7 (c 5.7, CH2Cl2). Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.35 (d, J = 9.1 Hz, 2 H), 7.24 (d, J = 9.1 Hz, 2 H), 7.10 (d, J = 7.7 Hz, 2 H), 6.99 
(d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.13 (dt, J = 4.2, 11.2 Hz, 1 H), 
4.03 (dt, J = 2.8, 8.4 Hz, 1 H), 3.75 (ddt, J = 2.8, 4.9, 11.2 Hz, 1 H), 2.93 (dd, J = 4.2, 14.0 Hz, 1 
H), 2.79 (dd, J = 6.3, 13.3 Hz, 1 H), 2.60 (dd, J = 10.5, 14.0 Hz, 1 H), 2.10–2.00 (m, 3 H), 1.98–
1.92 (m, 1 H), 1.86 (dd, J = 6.3, 12.6 Hz, 1 H) 1.67–1.57 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 
153.5, 147.9, 140.7, 136.7, 135.5, 131.5, 130.3, 129.3, 129.1, 121.2, 117.0, 59.6, 57.5, 52.6, 
39.1, 37.6, 30.8, 30.3, 27.8 (the CF3 carbon signal could not be determined due to the 
appearance of carbon signals from the minor diastereomer in the CF3 region of the spectrum); 
IR (film) 1642 cm–1. MS (ESI) 465.1557 (465.1551 calcd for C24H24ClF3N2O2, M + H+). The 
enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 17.1 and 19.8 min). 
 
N
NO
H
H
Cl
H
OCF3
 
(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8o). A modified 
general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 1-bromo-4-
(trifluoromethoxy)benzene (45 µL, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 48 mg (52%) of the title compound as a pale yellow oil and as an 17:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D –55.6 (c 1.5, CH2Cl2). The 
enantiopurity was determined to be 93:7 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 16.8 and 19.8 min). Spectroscopic data 
were identical to those provided above. 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methoxybenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8p). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 3-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 61 mg 
(74%) of the title compound as a yellow brown solid and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –65.1 (c 2.8, CH2Cl2). Mp = 132–137 ºC.  Data are for 
the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 9.1 Hz, 2 
H), 7.18 (t, J = 8.4 Hz, 1 H), 6.74 (dd, J = 2.1, 8.4 Hz, 1 H), 6.57 (d, J = 7.0 Hz, 1 H), 6.50 (s, 1 
H), 5.77–5.71 (m, 1 H), 5.04 (dd, J = 1.4, 16.8 Hz, 1 H), 5.01 (dd, J = 1.4, 9.8 Hz, 1 H), 4.14 (dt, 
J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.78–3.73 (m, 1 H), 2.91 (dd, 
J = 3.5, 13.3 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.54 (dd, J = 11.2, 14.0 Hz, 1 H), 2.10–
2.04 (m, 2 H), 2.03–1.99 (m, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, J = 6.3, 12.6 Hz, 1 H), 1.65–
1.56 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 159.7, 153.6, 140.7, 139.2, 135.6, 131.4, 129.6, 
129.3, 129.0, 121.4, 117.0, 115.3, 111.3, 59.6, 57.5, 55.2, 52.7, 39.7, 37.6, 30.8, 30.3, 27.8; IR 
(film) 1642 cm–1. MS (ESI) 411.1841 (411.1834 calcd for C24H27ClN2O2, M + H+). The 
enantiopurity was determined to be 87:13 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 248 nm, RT= 27.2 and 30.6 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(napthalen-2-ylmethyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8q). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 2-bromonapthanlene (62 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 
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66 mg (77%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –77.9 (c 4.6, CH2Cl2). Data are for the major isomer. Mp 
= 63–65 ºC. 1H NMR (700 MHz, CDCl3) δ 7.80 (d, J = 7.7 Hz, 1 H), 7.75 (t, J  = 7.7 Hz, 2 H), 
7.47–7.44 (m, 3 H), 7.38 (d, J = 9.1 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 7.07 (dd, J = 0.7, 8.4 Hz, 
1 H), 5.78–5.72 (m, 1 H), 5.04 (d, J = 16.8 Hz, 1 H), 5.02 (d, J = 9.8 Hz, 1 H), 4.25 (dt, J = 4.2, 
11.2 Hz, 1 H), 4.06 (dt, J = 2.1, 9.8 Hz, 1 H), 3.84 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 3.11 (dd, J = 
3.5, 14.0 Hz, 1 H), 2.81 (dd, J = 5.6, 13.3 Hz, 1 H), 2.74 (dd, J = 11.9, 14.0, Hz, 1 H), 2.11–2.05 
(m, 2 H), 2.04–1.94 (m, 2 H), 1.86 (dd, J = 7.0, 12.6 Hz, 1 H), 1.65–1.56 (m, 2 H); 13C NMR (175 
MHz, CDCl3) δ 153.6, 140.8, 135.6, 135.1, 133.4, 132.2, 131.4, 130.4, 129.4, 129.1, 128.4, 
127.7, 127.3, 127.1, 126.3, 125.7, 117.0, 59.6, 57.5, 52.7, 37.6, 30.8, 31.0, 30.2, 27.8;  IR (film) 
1646 cm–1. MS (ESI) 431.1886 (431.1885 calcd for C27H27ClN2O, M + H+). The enantiopurity 
was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% 
IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 24.4and 28.2 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylbenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (8r). The general procedure was employed for the coupling of 7c (61 
mg, 0.2 mmol) and 2-bromotoluene (36 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 65 mg 
(82%) of the title compound as a pale brown oil and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –30.1 (c 5.7, CH2Cl2). Data are for the major isomer. 1H 
NMR (700 MHz, CDCl3) δ 7.36 (d, J = 9.1 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.11–7.08 (m, 3 
H), 6.93–6.92 (m, 1 H), 5.78–5.71 (m, 1 H), 5.04 (dd, J = 1.4, 17.5 Hz, 1 H), 5.01 (dd, J = 1.4, 
10.5 Hz, 1 H), 4.09 (dt, J = 4.2, 12.6 Hz, 1 H), 4.04 (dt, J = 2.8, 9.1 Hz, 1 H), 3.86 (ddt, J = 2.8, 
5.6, 11.2 Hz, 1 H), 2.93 (dd, J = 3.5, 14.0 Hz, 1 H), 2.80 (dd, J = 5.6, 12.6 Hz, 1 H), 2.62 (dd, J = 
11.2, 14.0 Hz, 1 H), 2.11–2.02 (m, 3 H), 2.01 (s, 3 H), 1.99–1.94 (m, 1 H), 1.87 (dd, J = 6.3, 
12.6 Hz, 1 H), 1.65 (ddd, J = 6.3, 11.2, 17.5 Hz, 1 H), 1.58 (dt, J = 5.6, 12.6 Hz, 1 H); 13C NMR 
(175 MHz, CDCl3) δ 153.6, 140.7, 136.3, 135.7, 135.6, 131.5, 130.6, 130.3, 129.6, 129.0, 126.8, 
126.0, 117.0, 58.4, 57.5, 52.9, 37.7, 36.8, 30.8, 30.1, 27.8, 19.2; IR (film) 1642 cm–1. MS (ESI) 
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395.1885 (395.1885 calcd for C24H27ClN2O, M + H+). The enantiopurity was determined to be 
71:29 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 
mL/min, λ 215 nm, RT= 20.1 and 24.3 min). 
 
Deprotection of Bicyclic Urea Product 8c 
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(–)-(Z,3S,4aS,7R)-N-{4-[7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-
2(1H)-yl]phenyl}acetamide (S3). A flame-dried screwtop-flask was cooled under vacuum and 
charged with Pd2(dba)3 (5.2 mg, 0.006 mmol), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-
2’,4’,6’-triisopropyl-1,1’-biphenyl (13.7 mg, 0.03 mmol), K3PO4 (182 mg, 0.86 mmol) and 
acetamide (50.8 mg, 0.86 mmol). The flask was evacuated and backfilled with N2, and then a 
solution of 8c (206 mg, 0.57 mmol) in tert-butanol (3 mL) was added via syringe. The flask was 
sealed, heated to 110 ºC and stirred overnight (14 h). The mixture was cooled to room 
temperature and the mixture was filtered through a plug of celite, eluted with EtOAc (10 mL), 
and concentrated in vacuo. The crude material was purified by flash chromatography on silica 
gel to afford 191 mg (88%) of the title compound as a foamy brown solid: mp = 38–42 ºC. [α]23D 
–25.2 (c 5.3, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 8.93 (s, 1 H), 7.21 (d, J = 8.4 Hz, 2 H), 6.98 
(d, J = 8.4 Hz, 2 H), 5.77–5.72 (m, 1 H), 5.49–5.40 (m, 1 H), 5.07–5.03 (m, 3 H), 4.03 (dt, J = 
2.8, 9.1 Hz, 1 H), 3.77 (dt, J = 4.2, 10.5 Hz, 1 H), 3.67 (ddt, J = 2.8, 4.9, 8.4 Hz, 1 H), 2.80 (dd, J 
= 4.9, 12.6 Hz, 1 H), 2.25–2.08 (m, 4 H), 2.05 (s, 3 H) 2.02–1.98 (m, 1 H), 1.95–1.85 (m, 4 H), 
1.70–1.64 (m, 2 H), 0.88 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 168.8, 154.5, 137.3, 
136.6, 135.5, 134.8, 128.3, 124.0, 121.3, 117.1, 58.5, 57.3, 52.8, 37.8, 31.2, 31.0, 30.8, 27.7, 
24.0, 20.8, 14.1; IR (film) 3263, 1687, 1624 cm–1. MS (ESI) 382.2493 (382.2489 calcd for 
C23H31N3O2, M + H+). 
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(–)-(Z,3S,4aS,7R)-7-Allyl-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (9).  
A Schlenk tube was charged with a stirbar, S3 (39 mg, 0.1 mmol) and CH3CN (1 mL). A solution 
of ceric ammonium nitrate (164 mg, 0.3 mmol) in H2O (1 mL) was added to the reaction flask 
and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 oC for 15 min 
before being cooled to rt, at which time EtOAc (5 mL) was added. The mixture was transferred 
to a separatory funnel and the layers were separated. The organic layer was washed with 
saturated aqueous Na2SO3 (5 mL), saturated aqueous NaHCO3 (5 mL), and brine (5 mL). The 
organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude material was purified by flash chromatography (2% MeOH in CH2Cl2) on silica gel to 
afford 19 mg (77%) of the title compound as a yellow brown solid: [α]23D –63.2 (c 0.5, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 5.80–5.72 (m, 1 H), 5.57–5.51 (m, 1 H), 5.30–5.25 (m, 1 H), 5.06–
5.02 (m, 2 H), 4.73 (s, 1 H), 4.00 (dt, J = 3.0, 8.5 Hz, 1 H), 3.49 (ddt, J = 3.0, 5.5, 11.5 Hz, 1 H), 
3.46–3.41 (m, 1 H), 2.72 (d, J = 14.5 Hz, 1 H), 2.26–2.20 (m, 1 H), 2.13–1.93 (m, 6 H), 1.88–
1.77 (m, 2 H), 1.61–1.52 (m, 2 H), 0.96 (t, J = 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 155.1, 
135.6, 135.2, 124.0, 117.0, 56.2, 52.9, 50.0, 38.1, 35.7, 32.3, 30.7, 27.4, 20.8, 14.1; IR (film) 
3207, 1652 cm–1. MS (ESI) 249.1963 (249.1961 calcd for C15H24N2O, M + H+). 
 
Conversion of Bicyclic Urea Product 8c to Tricyclic Guanidine 12 
 
N
NHN
H
H C2H5
H
HCl
Cl  
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-imine hydrochloride (10). A flame-dried flask was cooled under a stream of 
N2 and charged with 8c (177 mg, 0.49 mmol) and toluene (5 mL). Freshly distilled POCl3 (2.5 
mL, 27 mmol) was added and the mixture was stirred at rt until the starting material had been 
consumed as judged by ESI+ MS analysis (ca. 3 hr).  The reaction mixture was cooled to rt and 
concentrated in vacuo. The crude product was dissolved in acetonitrile (5 mL) and a solution of 
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ammonia (20 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting 
material had been consumed as judged by ESI+ MS analysis (ca. 1 hr). The reaction mixture 
was concentrated and dissolved in methylene chloride (5 mL). Water (5 mL) was added and the 
mixture was transferred to a separatory funnel. The layers were separated and the organic layer 
was washed with saturated aqueous NaCl (3 x 10 mL). The combined aqueous layers were 
extracted with methylene chloride (3 x 10 mL). The combined organics layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified 
by flash chromatography on silica gel to afford 146 mg (75%) of the title compound as a pale 
white-yellow foam: [α]23D –45.5(c 1.1, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 7.48 (d, J = 7.7 Hz, 
1 H), 7.40 (d, J = 7.7 Hz, 1 H), 7.29 (d, J = 7.0 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 5.96–5.90 (m, 
1 H), 5.45 (dt, J = 7.0, 10.5 Hz, 1 H), 5.00–4.93 (m, 4 H), 3.75–3.72 (m, 1 H), 3.62–3.58 (m, 1 
H), 2.67 (d, J = 13.3 Hz, 1 H), 2.25 (dd, J = 2.1, 14.0 Hz, 1 H), 2.18–2.16 (m, 1 H) 2.12–2.06 (m, 
3 H), 2.03–1.93 (m, 2 H), 1.81–1.68 (m, 4 H), 0.82 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 151.3, 136.6, 136.1, 135.8, 134.5, 131.5, 131.4, 130.8, 128.9, 121.7, 118.3, 59.5, 59.1, 
53.1, 36.2, 30.8, 30.4, 29.6, 28.1, 20.8, 13.9; IR (film) 3457, 3275, 1636 cm–1. MS (ESI) 
358.2048 (358.2045 calcd for C21H29ClN3, M+).  
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(–)-(Z,2aS,4S,7S,8aR)-5-(4-Chlorophenyl)-7-methyl-4-(pent-2-en-1-yl)-1,2,2a,3,4,5,6,7,8,8a-
decahydro-2a1,5,6-triazaacenaphthylen-2a1-ium chloride (12). A test tube was charged with 
10 (39.4 mg, 0.1 mmol), PdCl2 (3.5 mg, 0.02 mmol), and CuCl (14.8 mg, 0.15 mmol). The tube 
was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled 
balloon attached to a needle (via an adaptor) was connected to the tube through the septum.  A 
solution of THF and H2O (7:1, 1.0 mL) was added to the test tube and the mixture was stirred at 
rt until the starting material had been consumed as judged by ESI+ MS analysis (ca. 4 hr). 
Methanol (1 mL) and NaCNBH3 (62.8 mg, 1.0 mmol) was added and the mixture was heated to 
50 oC until the starting material had been consumed as judged by ESI+ MS analysis (ca. 3 hr). 
The reaction mixture was cooled to rt and concentrated in vacuo. The crude product was 
dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and 
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2 M HCl (10 mL) was added. The layers were separated and the organic layer was washed with 
NH4OH (10 mL) to potentially remove any excess copper. The layers were separated and the 
organic layer was washed with 2 M HCl (10 mL). The organics layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 31 mg (79%) of the title compound as a pale white-tan oil 
and as a 5:1 mixture of diastereomers as determined by 1H NMR analysis: [α]23D –38.1 (c 0.6, 
CH2Cl2). Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.5 Hz, 2 H), 
7.34 (d, J = 8.5 Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 
H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, J = 3.5, 13.0 Hz, 1 H), 
1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, J = 6.5 Hz, 3 H), 0.93 (t, J 
= 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 148.6, 136.6, 136.5, 135.2, 132.0–129.0 (br, 2 C), 
121.9, 59.8, 57.7, 52.1, 47.4, 34.8, 30.0, 29.9, 29.6, 29.4, 20.9, 20.6, 14.0; IR (film) 3276, 1607 
cm–1. MS (ESI) 358.2047 (358.2045 calcd for C21H29ClN3, M +).  
 
Conversion of Bicyclic Urea Product 8c to 9-epi-Batzelladine K 16 
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(–)-(Z,3S,4aS,7R)-N-{4-[1-Oxo-7-(2-oxopropyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-2(1H)-yl]phenyl}acetamide (13). A test tube was charged with S3 (300 mg, 0.79 
mmol), PdCl2 (28 mg, 0.16 mmol), and CuCl (117 mg, 1.18 mmol). The tube was capped with a 
rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon attached to a 
needle (via an adaptor) was connected to the tube through the septum.  A solution of DMF and 
H2O (7:1, 8.0 mL) was added to the test tube and the mixture was stirred at rt until the starting 
material had been consumed as judged by ESI+ MS analysis (ca. 4 hr). EtOAc (20 mL) and 
brine (20 mL) was added and the mixture was transferred to a separatory funnel. The layers 
were separated and the organic layer was washed with NH4OH (5 mL) to potentially remove any 
excess copper. The combined aqueous layers were than extracted with EtOAc (20 mL). The 
organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. 
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The crude material was purified by flash chromatography on silica gel to afford 230 mg (74%) of 
the title compound as a pale yellow-pink solid: mp = 68–72 ºC. [α]23D –38.8 (c 0.8, CH2Cl2). 1H 
NMR (700 MHz, CDCl3) δ 8.66 (s, 1 H), 7.25 (d, J = 8.4 Hz, 2 H), 7.01 (d, J = 9.1 Hz, 2 H), 5.44–
5.41 (m, 1 H), 5.06–5.03 (m, 1 H), 4.37–4.34 (m, 1 H), 3.80–3.77 (m, 1 H), 3.66 (ddd, J = 2.8, 
4.9, 11.2 Hz, 1 H), 3.44 (dd, J = 2.8, 9.8 Hz, 1 H), 2.31 (dd, J = 9.8, 16.8 Hz, 1 H), 2.26–2.13 (m, 
3 H), 2.10 (s, 3 H), 2.06 (s, 3 H), 2.09–2.03 (m, 2 H), 1.91–1.86 (m, 2 H), 1.77 (dd, J = 7.0, 13.3 
Hz, 1 H), 1.65–1.58 (m, 2 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 207.5, 
168.7, 154.2, 137.2, 136.7, 134.9, 128.3, 123.8, 121.1, 58.5, 53.7, 52.8, 47.6, 31.1, 30.8, 30.2, 
29.4, 24.0, 20.8, 14.0 (one carbon signal is absent due to incidental equivalence); IR (film) 
3261, 1711, 1687, 1621 cm–1. MS (ESI) 398.2439 (398.2438 calcd for C23H31N3O3, M + H+).  
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N
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H
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(–)-(3S,4aS,7R)-7-(2-Oxopropyl)-3-pentylhexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (14). 
A flame-dried flask was cooled under vacuum and charged with 13 (100 mg, 0.25 mmol) and 
Pd/C (10 mg). The flask was capped with a rubber septum, was briefly flushed with hydrogen 
and then a hydrogen-filled balloon attached to a needle (via an adaptor) was connected to the 
flask through the septum.  Methanol (2.5 mL) was added to the flask and the mixture was stirred 
at rt until the starting material had been consumed as judged by ESI+ MS analysis (ca. 45 min). 
The crude product was then filtered through a plug of celite to remove the Pd/C and washed 
with methanol (5 mL). The crude material was concentrated in vacuo and carried on to the next 
step without further purification. The crude product was dissolved in CH3CN (10 mL) and 
transferred to a round-bottom flask charged with a stirbar. A solution of ceric ammonium nitrate 
(123 mg, 0.75 mmol) in H2O (30 mL) was added to the reaction flask and the mixture was stirred 
at rt for 5 min. The mixture was then heated at 50 oC for 4 hr before being cooled to rt, at which 
time EtOAc (25 mL) was added. The mixture was transferred to a separatory funnel and the 
layers were separated. The organic layer was washed with saturated aqueous Na2SO3 (15 mL), 
saturated aqueous NaHCO3 (15 mL), and brine (15 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified 
by flash chromatography on silica gel to afford 34 mg (51%) of the title compound as a white 
solid: mp = 84–88 ºC. [α]23D –11.7 (c 2.5, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 4.79 (s, 1 H), 
4.30–4.28 (m, 1 H), 3.48–3.45 (m, 1 H), 3.43–3.39 (m, 2 H), 2.29 (dd, J = 9.8, 16.8 Hz, 1 H), 
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2.10 (s, 3 H), 2.03–1.98 (m, 2 H), 1.95–1.94 (m, 1 H), 1.72 (dd, J = 7.7, 12.6 Hz, 1 H),  1.54–
1.46 (m, 3 H), 1.38–1.25 (m, 7 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 207.7, 
155.0, 52.8, 52.8, 50.0, 47.6, 37.8, 32.9, 31.6, 30.6, 30.3, 29.0, 25.5, 22.6, 14.0; IR (film) 3207, 
1709, 1649 cm–1. MS (ESI) 267.2065 (267.2067 calcd for C15H26N2O2, M + H+). 
 
N
H
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N
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H H
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(–)-9-epi-Batzelladine K (16). A flame-dried flask was cooled under vacuum and charged with 
14 (25 mg, 0.09 mmol) and dichloromethane (0.9 mL). 2,6-di-tert-butylpyridine (203 µL, 0.94 
mmol) and MeOTf (103 µL, 0.94 mmol) were added and the mixture was stirred at rt until the 
starting material had been consumed as judged by ESI+ MS analysis (ca. 1 hr). The solvent was 
then removed in a hood by blowing a constant stream of N2 over the stirring mixture. The 
solution was then poured in diethyl ether (20 ml) and washed with 1 M NaOH (10 mL) and brine 
(10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. The crude material was used without further purification. The crude O-methylisourea 
was dissolved in methanol (2 mL) and transferred to a thick walled glass vial at which time 
ammonium chloride (10.1mg, 0.19 mmol) was added to this solution. Anhydrous ammonia was 
bubbled through this solution for ~15 min before the reaction vessel was sealed and heated to 
60 oC overnight (14 hr).  The reaction was cooled to rt and concentrated in vacuo. The crude 
guanidine product 15 was used without further purification. Crude product 15 was dissolved in 
methanol (3 mL), NaCNBH3 (59 mg, 0.94 mmol) was added and the mixture was heated to 50 
oC until the starting material had been consumed as judged by ESI+ MS analysis (ca. 12 hr). 
The reaction mixture was cooled to rt and concentrated in vacuo. The crude product was 
dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and 
washed with 2 M HCl (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was 
determined to be a 3:1 mixture of diastereomers by 1H NMR analysis. The crude material was 
purified by flash chromatography on silica gel to afford 13 mg (48%) of the title compound as a 
pale yellow oil. The following data is for the pure isolated major diastereomer. [α]23D –43.8 (c 
0.5, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 3.80–3.73 (m, 2 H), 3.58–3.53 (m, 1 H), 3.52–3.49 
(m, 1 H), 2.26–2.21 (m, 3 H), 2.19 (dd, J = 4.2, 13.3 Hz, 1 H), 1.73–1.64 (m, 2 H), 1.60–1.56 (m, 
2 H), 1.52–1.47 (m, 1 H), 1.44–1.27 (m, 7 H), 1.27 (d, J = 6.3 Hz, 3 H), 0.93 (t, J = 7.0 Hz, 3 H); 
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13C NMR (175 MHz, CDCl3) δ 149.4, 56.3, 51.6, 48.4, 45.8, 36.2, 35.5, 31.5, 31.2, 30.5, 30.2, 
25.5, 22.4, 20.5, 14.0; 1H NMR (700 MHz, CD3OD) δ 7.56 (d, J = 7.5 Hz, 2 H), 7.34 (d, J = 8.5 
Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 
(m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, J = 3.5, 13.0 Hz, 1 H), 1.99–1.93 (m, 
3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, J = 6.5 Hz, 3 H), 0.93 (t, J = 7.5 Hz, 3 H); 
13C NMR (175 MHz, CD3OD) δ 150.4, 57.5, 53.5, 50.2, 47.3, 36.8, 36.1, 32.7, 31.9, 31.3, 30.7, 
26.8, 23.6, 20.8 14.3; IR (film) 3284, 3202, 1637 cm–1. MS (ESI) 250.2278 (250.2278 calcd for 
C15H28N3, M+).  
 
Assignment of Stereochemistry 
The relative stereochemistry of compound 8k was assigned on the basis of observed 1H NMR 
nOe experiments. Significant nOe relationships are shown below. The stereochemistry of all 
other bicyclic urea products was assigned based on analogy to 8k. 
8k
N
NO
H
H
Cl
H
Me
H
 
 
The relative stereochemistry of compounds 12 and 16 were assigned on the basis of observed 
1H NMR nOe experiments. Significant nOe relationships are shown below. 
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H
 
 
The absolute stereochemistry of the urea products was assigned via the synthesis of compound 
ent-8c from pent-4-enal via the route illustrated below in Scheme S1. The optical rotation of 
product ent-8c prepared via this route was opposite that of the product 8c generated in the Pd-
catalyzed carboamination reaction between 7c and Z-bromobutene. In addition, analysis of 
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product ent-8c by chiral HPLC indicated that ent-8c was the enantiomer of product 8c formed in 
the catalytic reaction. 
 
Scheme S1 
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(–)-(RS)-2-Methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide (S4). This compound was 
prepared according to the procedure reported by Ellman.[4] A flame-dried flask was cooled under 
a stream of N2 and charged with pent-4-enal (1.38 mL, 14 mmol) and THF (40 mL). Titanium 
ethoxide (4.2 mL, 20 mmol) was added and the reaction mixture was stirred at rt for 5 min. (R)- 
tert-butanesulfinamide (1.21 g, 10 mmol) was added in one portion and the mixture was stirred 
overnight (ca. 14 h) at rt. The reaction mixture was poured into brine (40 mL) and stirred for 10 
min. Ethyl acetate (20 mL) was added, the mixture was filtered through celite and the celite was 
washed with ethyl acetate (50 mL). The mixture was transferred to a separatory funnel, brine 
(20 mL) was added, and the layers were separated. The aqueous phase was extracted with 
ethyl acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 1.38 g (74%) of the title compound as a colorless oil. 
Spectroscopic properties are identical to those previously reported.[5] 1H NMR (500 MHz, CDCl3) 
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δ 8.08 (t, J = 4.5 Hz, 1 H), 5.84 (ddt, J = 4.5, 10.0, 17.0 Hz, 1 H), 5.08 (dd, J = 1.5, 17.0 Hz, 1 
H), 5.02 (dd, J = 1.5, 10.0 Hz, 1 H), 2.63 (td, J = 4.0, 7.5 Hz, 2 H), 2.40 (q, J = 7.0 Hz, 2 H), 1.19 
(s, 9 H). 
 
NHS
tBu
O
 
(RS, 4R)-2-Methyl-N-(octa-1,7-dien-4-yl)propane-2-sulfinamide (S5). A flame-dried flask was 
cooled under a stream of N2 and charged with freshly ground magnesium turnings (720 mg, 4 
equiv). The magnesium was suspended in ether (14.8 mL, 1 M), cooled to 0 oC in an ice/water 
bath and allyl bromide (1.28 mL, 14.8 mmol) was added dropwise. After addition, the ice bath 
was removed, and the reaction mixture was stirred at rt for 30 min. Stirring was stopped and the 
solution was filtered through glass wool prior to addition to S4. A flame-dried flask was cooled 
under a stream of N2 and charged with S4 (1.38 g, 7.4 mmol) and THF (37 mL, 0.2 M). The 
sulfinyl imine solution was cooled to 0 oC in an ice/water bath before the filtered Grignard 
reagent solution was added dropwise. The reaction mixture was stirred at 0 oC until the starting 
material had been completely consumed as judged by TLC analysis (1 h). Water was then 
added dropwise until precipitation of magnesium salts occurred and the resulting solution was 
decanted into a separate flask. The solution was dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. Analysis of the crude product by 1H NMR indicated that a 10:1 
mixture of diastereomers had formed. The crude material was purified by flash chromatography 
on silica gel to afford 1.02 g (60%) of the title compound as a 10:1 mixture of diastereomers as 
a clear colorless oil. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) d 5.83–5.74 (m, 
2 H), 5.18–4.97 (m, 4 H), 3.36–3.32 (m, 1 H), 3.21 (d, J = 6.5 Hz, 1 H), 2.45–2.40 (m, 1 H), 
2.37–2.32 (m, 1 H), 2.18–2.08 (m, 2 H), 1.62–1.58 (m, 2 H), 1.21 (s, 9 H). 
 
 
 
NHBoc
 
(R)-tert-Butyl octa-1,7-dien-4-ylcarbamate (S1). A flame-dried flask was cooled under a 
stream of N2 and charged with S5 (1.02 g, 4.4 mmol) and methanol (22 mL). A solution of 
anhydrous hydrochloric acid (4.4 mL, 17.7 mmol, 4 M in dioxane) was added and the mixture 
was stirred at rt for 1 h, at which time TLC analysis indicated that the starting material had been 
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completely consumed. The reaction mixture was diluted with water (10 mL) and CH2Cl2 (10 mL), 
basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was dissolved in THF (44 mL, 0.1 M), solid di-tert-butyldicarbonate (1.2 g, 5.3 mmol) 
was added and the reaction mixture was stirred at rt for 3 h. 1 M NaOH (5 mL) was added and 
the resulting biphasic mixture was stirred for 1 h at rt. The mixture was transferred to a 
separatory funnel, the layers were separated and the aqueous layer was extracted with ethyl 
acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel to afford 941 mg (94%) of the title compound as a clear colorless oil. The 
spectroscopic properties of this compound were identical to that of compound (±)-S1 described 
above. 
 
N
Boc
TMS
HH
 
(E,2R,5S)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2). A flame-
dried Schlenk flask was cooled under a stream of N2 and charged with Pd2(dba)3 (77 mg, 0.084 
mmol), tri(2-furyl)phosphine (77 mg, 0.33 mmol) and NaOtBu (802 mg, 8.4 mmol). The flask was 
purged with N2, then a solution of (R)-S1 (941 mg, 4.2 mmol) in freshly distilled xylenes (21 mL) 
was added via syringe and the resulting mixture was stirred at rt for 2 min. (E)-(2-
bromovinyl)trimethylsilane (1.28 mL, 8.4 mmol) was added and the flask was heated to 140 ºC 
and stirred for 3 h. The mixture was cooled to room temperature and saturated aqueous NH4Cl 
(10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer 
was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 
mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. 
The crude material was purified by flash chromatography on silica gel to afford 647 g (48%) of 
the title compound as a dark brown oil. The spectroscopic properties of this compound were 
identical to that of compound (±)-S2 described above. 
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(E,2R,5S)-2-Allyl-N-(4-chlorophenyl)-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxamide 
(S6). A round-bottom flask equipped with a stirbar was charged with (E,2R,5S)-S2 (647 mg, 2.0 
mmol) and dichloromethane (20 mL, 0.1 M). Trifluoroacetic acid (2.0 mL, 1.0 M) was added to 
the flask and the mixture was stirred for 20 min at rt. The solution was diluted with water, 
basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was dissolved in dichloromethane (20 mL, 0.1 M) and 4-chlorophenyl isocyanate (369 
mg, 1.2 equiv) was added. The reaction mixture was stirred at rt for 1 h until starting material 
had been completely consumed as judged by TLC analysis. The crude reaction mixture was 
concentrated in vacuo, and purified by flash chromatography on silica gel to afford 244 mg 
(32%) of the title compound as a orange brown oil.  1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 9.0 
Hz, 2 H), 7.22 (d, J = 9.0 Hz, 2 H), 6.41 (s, 1 H), 6.04 (dt, J = 7.0, 18.5 Hz, 1 H), 5.93–5.84 (m, 1 
H), 5.82 (d, J = 18.5 Hz, 1 H), 5.22–5.17 (m, 2 H), 4.02–3.95 (m, 2 H), 2.61–2.52 (m, 2 H), 2.35 
(dt, J = 7.0, 13.5 Hz, 1 H), 2.24 (dt, J = 7.5, 14.0 Hz, 1 H), 2.02–1.96 (m, 2 H), 1.80–1.74 (m, 2 
H), 0.05 (s, 9 H). 
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(E,Z,3R,4aR,7S)-2-(4-Chlorophenyl)-3-(pent-2-en-1-yl)-7-[3-
(trimethylsilyl)allyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (S7). A flame-dried Schlenk 
tube was cooled under vacuum and charged with Pd2(dba)3 (3.1 mg, 0.003 mmol), PCy3.HBF4 
(5.0 mg, 0.014 mmol) and NaOtBu (25 mg, 0.26 mmol). The flask was evacuated and purged 
with N2. A solution of S6 (65 mg, 0.17 mmol) in toluene (0.85 mL) was added via syringe and 
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the resulting mixture was stirred at rt for 2 min. (Z)-1-bromobut-1-ene (130 µL, 0.26 mmol, 2.0 M 
solution in toluene) was added and the tube was heated to 100 ºC and stirred until the starting 
material was completely consumed as judged by TLC analysis (1 h). The mixture was cooled to 
room temperature and saturated aqueous NH4Cl (1 mL) and ethyl acetate (1 mL) were added. 
The layers were separated, the organic layer was filtered through a plug of silica gel, and the 
silica gel was washed with ethyl acetate (1 mL). The filtrate was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 53 mg (71%) of the title compound as a yellow oil.  1H 
NMR (500 MHz, CDCl3) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.19 (d, J = 9.0 Hz, 2 H), 5.94 (ddd, J = 6.0, 
7.5, 18.5 Hz, 1 H), 5.68 (d, J = 18.5 Hz, 1 H), 5.47–5.42 (m, 1 H), 5.12–5.07 (m, 1 H), 4.03 (dt, J 
= 2.5, 8.5 Hz, 1 H), 3.90 (dt, J = 4.5, 9.5 Hz, 1 H), 3.66 (ddt, J = 2.5, 5.0, 11.5 Hz, 1 H), 2.73 
(dd, J = 5.5, 12.5 Hz, 1 H), 2.27–2.16 (m, 4 H), 2.01–1.89 (m, 4 H), 1.84–1.81 (m, 1 H), 1.69–
1.61 (m, 2 H), 0.90 (t, J = 7.5 Hz, 3 H), 0.03 (s, 9 H). 
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(+)-(Z,3R,4aR,7S)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (ent-8c). A Schlenk tube was charged with S7 (53 mg, 0.12 mmol) and 
CH2Cl2 (1.2 mL). TFA (0.6 mL) was added and the reaction mixture was stirred overnight at 40 
ºC. The reaction mixture was then cooled to rt, diluted with water (1 mL), and basified with 
NH4OH to pH > 12. The reaction mixture was transferred to a separatory funnel and the layers 
were separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel.  
This procedure afforded 29 mg (67%) of the title compound as a yellow oil: [α]23D +17.7 (c 2.9, 
CH2Cl2). The spectroscopic properties of this compound were identical to that of compound 8c. 
The enantiopurity was determined to be 10:90 er by chiral HPLC analysis (chiralcel ADH, 25 cm 
x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 17.8 min). 
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